4.71
+3.52%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ascletis Pharma
Its shares trade on HKEX under the ticker 1672.HK. It has been listed since 1 August 2018. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.4m and a net loss of CN¥419.1m. At that date it held total assets of CN¥2.41bn and shareholders' equity of CN¥2.25bn.
Ascletis Pharma, Inc. operates as biotechnology firm to test the waters. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2018-08-01. The firm is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 1 Aug 2018
- Employees
- 285
- Website
- ascletis.com ↗
Leadership
Pay as last reported
- Dr. Jinzi Jason WuExecutive Chairman of the Board, Chief Executive Officer, since 2013CN¥19.9m
- Mrs. Judy Hejingdao WuSenior Vice President, Executive Director, since 2014CN¥2.5m
- Ms. Yuemei YanSenior Vice President of Clinical Development and Operations, Sales Director
- Dr. Handan HeChief Scientific Officer
- Mr. Ming Fai ChungCompany Secretary
- Mr. Jiong GuNon-Executive Independent DirectorCN¥369,000
- Ms. Lin HuaNon-Executive Independent DirectorCN¥369,000
- Dr. Yizhen WeiNon-Executive Independent DirectorCN¥369,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ascletis Pharma Inc has a strong and experienced management team that possesses deep knowledge and expertise in the pharmaceutical industry. This allows them to make informed decisions and navigate the complex regulatory environment effectively.
- The company has a diverse pipeline of innovative and high-quality products. This enables Ascletis Pharma Inc to expand its product portfolio and cater to a wide range of therapeutic areas, thereby reducing dependence on a single drug or market.
Weaknesses
- Ascletis Pharma Inc may face challenges in terms of limited financial resources compared to larger pharmaceutical companies. This could potentially hinder their ability to invest in research and development, marketing, and expanding manufacturing capabilities.
- The company might also face difficulties in protecting its intellectual property rights. As the pharmaceutical market is highly competitive, there is a risk of imitation or infringement by competitors, which can impact Ascletis Pharma Inc's market share and profitability.
Opportunities
- Ascletis Pharma Inc can leverage the growing demand for innovative and effective treatments in emerging markets. Expanding into these markets can drive revenue growth and diversify the customer base.
- Additionally, collaborations and partnerships with other pharmaceutical companies or research institutions can provide opportunities for knowledge sharing, access to new technologies, and joint product development, enabling Ascletis Pharma Inc to advance its pipeline and expand its market reach.
Threats
- Ascletis Pharma Inc faces the risk of increased competition from both established pharmaceutical companies and emerging players. This can impact pricing power, market share, and overall profitability.
- Regulatory challenges and changes in government policies can also pose a threat to Ascletis Pharma Inc's operations. Strict regulations or delays in regulatory approvals of new products can significantly affect timelines, product launches, and revenue generation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.